<DOC>
	<DOCNO>NCT00373906</DOCNO>
	<brief_summary>Bortezomib treatment disseminate MALT lymphoma relapse follow HP -eradication , chemotherapy radiation .</brief_summary>
	<brief_title>Velcade MALT Lymphoma Patients</brief_title>
	<detailed_description>The objective study evaluate effectivity safety bortezomib patient disseminate MALT lymphoma relapse follow HP-eradication , chemotherapy radiation . It phase II prospective single arm study target sample 16 patient . 1.5mg/m2 Bortezomib give intravenously day 1,4,8,11 every three week , maximum 8cycles .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>patient histologically confirm MALT lymphoma measurable disease ( stage IIV ) first great relapse HPeradication , radiation chemotherapy , age &gt; 18 year must able tolerate therapy adequate cardiac , renal hepatic function ECOG status &lt; _ 2 must capable understand purpose study give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>MALT Lymphoma , Bortezomib</keyword>
</DOC>